Study S000088

Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients: A Multicenter, Randomized, Open-Label Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07715929
Acronym: TEAR-AF
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: SINGLE
Status: NOT_YET_RECRUITING
Enrollment: 710
Start: 2026-09-01
Primary completion: 2029-09-01
Lead sponsor: Yunlong Wang
Conditions: Atrial Fibrillation; Obesity & Overweight; Catheter Ablation
Interventions: DRUG:Tirzepatide; BEHAVIORAL:Structured Lifestyle Intervention
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Number of Participants With Recurrence of Atrial Fibrillation, Atrial Flutter, or Atrial Tachycardia [Day 91 through Week 52 after catheter ablation]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.